Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H1 2017

  • ID: 4311817
  • Report
  • 103 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Amgen Inc
  • Astellas Pharma Inc
  • Blueprint Medicines Corp
  • Eli Lilly and Company
  • H3 Biomedicine Inc
  • Ionis Pharmaceuticals Inc
  • MORE
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H1 2017

Summary:

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) pipeline Target constitutes close to 24 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Fibroblast Growth Factor Receptor 4 - Pipeline Review, H1 2017, outlays comprehensive information on the Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Fibroblast growth factor receptor 4 is a protein encoded by the FGFR4 gene. It plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. It is required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. It phosphorylates PLCG1 and FRS2. Ligand binding leads to the activation of several signaling cascades. The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 10, 5, 5 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Metabolic Disorders, Gastrointestinal, Central Nervous System and Musculoskeletal Disorders which include indications Hepatocellular Carcinoma, Solid Tumor, Bile Duct Cancer (Cholangiocarcinoma), Type 2 Diabetes, Breast Cancer, Esophageal Cancer, Gastric Cancer, Lung Adenocarcinoma, Lymphoma, Melanoma, Non-Alcoholic Steatohepatitis (NASH), Non-Small Cell Lung Cancer, Obesity, Ovarian Cancer, Recurrent Glioblastoma Multiforme (GBM), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Chronic Lymphocytic Leukemia (CLL), Constipation, Endometrial Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Fibrosis, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Metastatic Biliary Tract Cancer, Metastatic Melanoma, Metastatic Transitional (Urothelial) Tract Cancer, Nasopharyngeal Cancer, Non-Small Cell Lung Carcinoma, Osteosarcoma, Peritoneal Cancer, Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis, Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Small-Cell Lung Cancer, Spinal Cord Injury, Thymic Carcinoma, Thyroid Cancer and Transitional Cell Cancer (Urothelial Cell Cancer).

Furthermore, this report also reviewsalso reviews key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1)
  • The report reviews Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amgen Inc
  • Astellas Pharma Inc
  • Blueprint Medicines Corp
  • Eli Lilly and Company
  • H3 Biomedicine Inc
  • Ionis Pharmaceuticals Inc
  • MORE
  1. Introduction
  2. Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Overview
  3. Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Therapeutics Development
  4. Products under Development by Stage of Development
  5. Products under Development by Therapy Area
  6. Products under Development by Indication
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Therapeutics Assessment
  10. Assessment by Mechanism of Action
  11. Assessment by Route of Administration
  12. Assessment by Molecule Type
  13. Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Companies Involved in Therapeutics Development
  14. Amgen Inc
  15. ArQule Inc
  16. Astellas Pharma Inc
  17. AstraZeneca Plc
  18. Blueprint Medicines Corp
  19. Bristol-Myers Squibb Company
  20. Eisai Co Ltd
  21. Eli Lilly and Company
  22. Genosco Inc
  23. H3 Biomedicine Inc
  24. Incyte Corp
  25. Ionis Pharmaceuticals Inc
  26. Johnson & Johnson
  27. NGM Biopharmaceuticals Inc
  28. Novartis AG
  29. Principia Biopharma Inc
  30. Tasly Pharmaceutical Group Co Ltd
  31. Vichem Chemie Research Ltd
  32. Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Drug Profiles
  33. ARQ-087 - Drug Profile
  34. Product Description
  35. Mechanism Of Action
  36. R&D Progress
  37. ASP-5878 - Drug Profile
  38. Product Description
  39. Mechanism Of Action
  40. R&D Progress
  41. AZ-709 - Drug Profile
  42. Product Description
  43. Mechanism Of Action
  44. R&D Progress
  45. BLU-554 - Drug Profile
  46. Product Description
  47. Mechanism Of Action
  48. R&D Progress
  49. BLU-9931 - Drug Profile
  50. Product Description
  51. Mechanism Of Action
  52. R&D Progress
  53. BMS-986036 - Drug Profile
  54. Product Description
  55. Mechanism Of Action
  56. R&D Progress
  57. erdafitinib - Drug Profile
  58. Product Description
  59. Mechanism Of Action
  60. R&D Progress
  61. ES-135 - Drug Profile
  62. Product Description
  63. Mechanism Of Action
  64. R&D Progress
  65. FGF-401 - Drug Profile
  66. Product Description
  67. Mechanism Of Action
  68. R&D Progress
  69. golvatinib tartrate + lenvatinib mesylate - Drug Profile
  70. Product Description
  71. Mechanism Of Action
  72. R&D Progress
  73. H-3B6527 - Drug Profile
  74. Product Description
  75. Mechanism Of Action
  76. R&D Progress
  77. INCB-62079 - Drug Profile
  78. Product Description
  79. Mechanism Of Action
  80. R&D Progress
  81. infigratinib - Drug Profile
  82. Product Description
  83. Mechanism Of Action
  84. R&D Progress
  85. IONIS-463588 - Drug Profile
  86. Product Description
  87. Mechanism Of Action
  88. R&D Progress
  89. lenvatinib mesylate - Drug Profile
  90. Product Description
  91. Mechanism Of Action
  92. R&D Progress
  93. LY-2874455 - Drug Profile
  94. Product Description
  95. Mechanism Of Action
  96. R&D Progress
  97. NGM-282 - Drug Profile
  98. Product Description
  99. Mechanism Of Action
  100. R&D Progress
  101. PRN-1371 - Drug Profile
  102. Product Description
  103. Mechanism Of Action
  104. R&D Progress
  105. Recombinant Protein 1 to Agonize Fibroblast Growth Factor Receptor for Fibrosis - Drug Profile
  106. Product Description
  107. Mechanism Of Action
  108. R&D Progress
  109. Recombinant Protein to Agonize FGFR for Type 2 Diabetes - Drug Profile
  110. Product Description
  111. Mechanism Of Action
  112. R&D Progress
  113. Recombinant Proteins to Agonize FGFR for Metabolic Disorders - Drug Profile
  114. Product Description
  115. Mechanism Of Action
  116. R&D Progress
  117. Small Molecule to Antagonize FGFR4 for Hepatocellular Carcinoma - Drug Profile
  118. Product Description
  119. Mechanism Of Action
  120. R&D Progress
  121. Small Molecules to Inhibit Pan FGFR for Oncology - Drug Profile
  122. Product Description
  123. Mechanism Of Action
  124. R&D Progress
  125. TSLB-1344 - Drug Profile
  126. Product Description
  127. Mechanism Of Action
  128. R&D Progress
  129. Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Dormant Products
  130. Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Discontinued Products
  131. Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Product Development Milestones
  132. Featured News & Press Releases
  133. Jun 05, 2017: Eisai to Present Results of Phase Ib/II Study of Anticancer Agent Lenvima (Lenvatinib) in Combination With Anti-PD-1 Antibody Pembrolizumab for the Treatment of Endometrial Carcinoma at 53rd ASCO Annual Meeting
  134. Jun 05, 2017: Eisai to Present Results of Phase III Trial of Lenvima (Lenvatinib) as First-line Treatment for Unresectable Hepatocellular Carcinoma in Oral Session at 53rd Asco Annual Meeting
  135. May 18, 2017: Eisai to Present Abstracts on Lenvatinib At 53rd ASCO Annual Meeting
  136. May 17, 2017: ArQule to Present Clinical Data on ARQ-087 at the 2017 American Society of Clinical Oncology Annual Meeting
  137. Apr 22, 2017: Bristol-Myers Squibb's BMS-986036 (Pegylated FGF21) Shows Consistent Improvement in Liver Fat, Liver Injury and Fibrosis in Patients with Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial
  138. Apr 22, 2017: NGM Bio Announces NGM282 Dramatically Reduced Liver Fat and Other Biomarkers Associated with Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial
  139. Apr 05, 2017: Eisai Presents Data Of Mechanisms Of Action Relating To Tumor Immune Response Regarding Combination Of Anticancer Agent Lenvatinib With Anti-PD-1 Antibody At AACR 108th Annual Meeting
  140. Apr 05, 2017: NGM Bio to Present Phase 2 Data of NGM282 in NASH at International Liver Congress
  141. Mar 28, 2017: Eisai to Present Data on Lenvima at 2017 AACR Annual Meeting
  142. Mar 28, 2017: German Federal Joint Committee (G-BA) Confirms Additional Benefit of Kisplyx (lenvatinib) in Treatment of Advanced Renal Cell Carcinoma
  143. Mar 27, 2017: Blueprint Medicines to Present on BLU-554 at Upcoming Scientific Conferences
  144. Mar 23, 2017: Mass. General team identifies mechanisms behind resistance to FGFR inhibitor drug
  145. Mar 09, 2017: H3 Biomedicine to Present on H3B-6527 at 2017 American Association of Cancer Research Annual Meeting
  146. Jan 25, 2017: Phase III Trial Of Anticancer Agent Lenvima As First-Line Treatment For Unresectable Hepatocellular Carcinoma Meets Primary Endpoint
  147. Jan 04, 2017: German Institute for Quality and Efficiency in Health Care Confirms Additional Benefit for Kisplyx (lenvatinib) in Combination with everolimus for the Treatment of Advanced Renal Cell Carcinoma
  148. Appendix
  149. Methodology
  150. Coverage
  151. Secondary Research
  152. Primary Research
  153. Expert Panel Validation
  154. Contact Us
  155. Disclaimer
List of Tables:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Indications, H1
  4. Number of Products under Development by Indications, H1 2017 (Contd..1), H1
  5. Number of Products under Development by Indications, H1 2017 (Contd..2), H1
  6. Number of Products under Development by Companies, H1
  7. Products under Development by Companies, H1
  8. Products under Development by Companies, H1 2017 (Contd..1), H1
  9. Products under Development by Companies, H1 2017 (Contd..2), H1
  10. Products under Development by Companies, H1 2017 (Contd..3), H1
  11. Products under Development by Companies, H1 2017 (Contd..4), H1
  12. Number of Products under Investigation by Universities/Institutes, H1
  13. Products under Investigation by Universities/Institutes, H1
  14. Number of Products by Stage and Mechanism of Actions, H1
  15. Number of Products by Stage and Route of Administration, H1
  16. Number of Products by Stage and Molecule Type, H1
  17. Pipeline by Amgen Inc, H1
  18. Pipeline by ArQule Inc, H1
  19. Pipeline by Astellas Pharma Inc, H1
  20. Pipeline by AstraZeneca Plc, H1
  21. Pipeline by Blueprint Medicines Corp, H1
  22. Pipeline by Bristol-Myers Squibb Company, H1
  23. Pipeline by Eisai Co Ltd, H1
  24. Pipeline by Eli Lilly and Company, H1
  25. Pipeline by Genosco Inc, H1
  26. Pipeline by H3 Biomedicine Inc, H1
  27. Pipeline by Incyte Corp, H1
  28. Pipeline by Ionis Pharmaceuticals Inc, H1
  29. Pipeline by Johnson & Johnson, H1
  30. Pipeline by NGM Biopharmaceuticals Inc, H1
  31. Pipeline by Novartis AG, H1
  32. Pipeline by Principia Biopharma Inc, H1
  33. Pipeline by Tasly Pharmaceutical Group Co Ltd, H1
  34. Pipeline by Vichem Chemie Research Ltd, H1
  35. Dormant Projects, H1
  36. Discontinued Products, H1
List of Figures:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Top 10 Indications, H1
  4. Number of Products by Mechanism of Actions, H1
  5. Number of Products by Stage and Mechanism of Actions, H1
  6. Number of Products by Routes of Administration, H1
  7. Number of Products by Stage and Routes of Administration, H1
  8. Number of Products by Molecule Types, H1
  9. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Amgen Inc
  • ArQule Inc
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Blueprint Medicines Corp
  • Bristol-Myers Squibb Company
  • Eisai Co Ltd
  • Eli Lilly and Company
  • Genosco Inc
  • H3 Biomedicine Inc
  • Incyte Corp
  • Ionis Pharmaceuticals Inc
  • Johnson & Johnson
  • NGM Biopharmaceuticals Inc
  • Novartis AG
  • Principia Biopharma Inc
  • Tasly Pharmaceutical Group Co Ltd
  • Vichem Chemie Research Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll